Stocktube video
10/10/2014

Summit Corporation's Pye on positive data for DMD treatment

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: SUMM
Latest Price: 132.50p  (0,00%)
52-week High: 178.00p
52-week Low: 6.25p
Market Cap: 54.41M
1 year chart More charts
Deal SUMM Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Summit plc
www.summitplc.com
Deal Summit plc Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

 

Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the...

Read more
Pdf

Summit Corp to present Alzheimer’s research data at Paris conference

July 19 2011, 9:06am Summit Corp is presenting the recently reported positive results from its programme targeting Alzheimer's disease and other neurological disorders at the Alzheimer's Association International Conference 2011 in Paris

Drug discovery group Summit Corporation PLC (LON:SUMM) said it is presenting the recently reported positive results from its programme targeting Alzheimer's disease and other neurological disorders at the Alzheimer's Association International Conference 2011 (ICAD 2011) which is currently being held in Paris.

Alzheimer's is a progressive and debilitating neurodegenerative disorder and is the most common form of dementia.  It remains an area of high unmet medical need with current treatment options only providing symptomatic relief. 

The presentation will highlight Summit's focus on a new and potentially disease modifying strategy for the treatment of Alzheimer's disease that targets the enzyme OGA (O-linked N-acetylglucosaminidase).

The company identifid and then optimised the generation of extremely potent, selective and non-cytotoxic inhibitors of OGA using its Seglin technology drug discovery platform.

Summit will also demonstrate in a human cellular model that the Seglin OGA inhibitors reduce levels of an abnormal form of the protein Tau, found in the brain of Alzheimer's patients and which causes the formation of toxic 'tangles' and ultimately results in disease symptoms.

Interest in the Tau protein as an approach for developing drugs to treat Alzheimer's disease continues to increase as evidenced by the growing number of peer-reviewed scientific publications, Summit said.

“As results from Summit's early-stage programme show, inhibition of OGA by Seglins can reduce the levels of hyperphosphorylated Tau and potentially offers a new strategy for treating this disease,” it added.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.